Tishtha Nivolumab 40mg Injection

Tishtha Nivolumab 40mg Injection works by targeting the PD-1/PD-L1 pathway. Many cancer cells use this pathway to "turn off" the immune system’s T-cells, allowing the tumor to grow unchecked. By blocking the PD-1 receptor, Nivolumab reactivates these T-cells, enabling them to seek out and eliminate cancer cells throughout the body. This mechanism often leads to long-term remission in patients who have not responded to traditional chemotherapy.

Key Clinical Benefits of Tishtha

• Broad-Spectrum Efficacy: Effective against a wide range of solid tumors and hematological malignancies.

• Improved Survival Rates: Proven to extend progression-free survival and overall survival in metastatic cancer patients.

• Zydus Quality Standards: Produced by Zydus, a global leader in biosimilar development, ensuring that Tishtha meets rigorous safety and purity benchmarks.

• Combination Potential: Frequently used in combination with other immunotherapies or targeted drugs to maximize tumor shrinkage.

Administration & Safety Protocols

1. Infusion Method: Administered as an Intravenous (IV) infusion over 30 to 60 minutes.

2. Dosing Schedule: Usually given every 2, 3, or 4 weeks, depending on the specific cancer type and the oncologist’s protocol.

3. Temperature Control: Must be refrigerated at 2°C to 8°C. Do not freeze or shake the vial.

4. Monitoring: Patients must be monitored for immune-related adverse events (irAEs), where the immune system may attack healthy organs like the lungs, liver, or colon.